Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Blood (2014) 124 (7): 1183–1191.

https://doi.org/10.1182/blood-2014-04-572545

Published: 2014

Journal Articles

Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia

Andromachi Scaradavou, Claudio G. Brunstein, Mary Eapen, Jennifer Le-Rademacher, Juliet N. Barker, Nelson Chao, Corey Cutler, Colleen Delaney, Fangyu Kan, Luis Isola, Chatchada Karanes, Mary J. Laughlin, John E. Wagner, Elizabeth J. Shpall

Blood (2013) 121 (5): 752–758.

https://doi.org/10.1182/blood-2012-08-449108

Published: 2013

Journal Articles

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis

Blood (2011) 118 (21): 1750.

https://doi.org/10.1182/blood.V118.21.1750.1750

Published: 2011

Journal Articles

Pharmacoeconomic Impact of Upfront Use Plerixafor for Autologous Stem Cell Mobilization in Multiple Myeloma Patients

Luis Isola, MD, Karen M Banoff, RN, MPA, BS, Sara S Kim, BS, Pharm.D., BCOP

Blood (2011) 118 (21): 2075.

https://doi.org/10.1182/blood.V118.21.2075.2075

Published: 2011

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Maria J. Nieto, MD, Eileen Scigliano, MD, Celia L. Grosskreutz, MD, Steven Fruchtman, MD, John Mascarenhas, MD, Keren Osman, MD, Adriana Malone, MD, Samuel Cytryn, Vesna Najfeld, PhD, Ronald Hoffman, MD, Luis Isola, MD

Blood (2011) 118 (21): 4534.

https://doi.org/10.1182/blood.V118.21.4534.4534

Published: 2011

Journal Articles

Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Robert J. Soiffer, Jennifer LeRademacher, Vincent Ho, Fangyu Kan, Andrew Artz, Richard E. Champlin, Steven Devine, Luis Isola, Hillard M. Lazarus, David I. Marks, David L. Porter, Edmund K. Waller, Mary M. Horowitz, Mary Eapen

Blood (2011) 117 (25): 6963–6970.

https://doi.org/10.1182/blood-2011-01-332007

Published: 2011

Includes: Supplemental data

Journal Articles

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis

Blood (2011) 117 (24): 6714–6720.

https://doi.org/10.1182/blood-2010-12-323824

Published: 2011

Journal Articles

Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis

Blood (2010) 116 (21): 898.

https://doi.org/10.1182/blood.V116.21.898.898

Published: 2010

Journal Articles

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Philip L. McCarthy, MD, Kouros Owzar, PhD, Kenneth C. Anderson, Craig C. Hofmeister, MD, David Duane Hurd, MD, Hani Hassoun, MD, Sergio Giralt, MD, Edward A. Stadtmauer, MD, Paul G Richardson, MD, Daniel J. Weisdorf, MD, Ravi Vij, MBBS, MD, Jan S Moreb, MD, Natalie Scott Callander, MD, Koen Van Besien, MD, Teresa Gentile, MD, PhD, Luis Isola, MD, Richard T Maziarz, MD, Don A. Gabriel, MD, PhD, Asad Bashey, MD, PhD, Heather Landau, MD, Thomas Martin, MD, Muzaffar H. Qazilbash, MD, Denise Levitan, MD, Brian McClune, MD, Vera Hars, MS, John Postiglione, BA, Chen Jiang, PhD, Elizabeth Bennett, BS, Susan S Barry, BA, Linda Bressler, PharmD, Michael Kelly, MA, Michele Sexton, MS, Cara Rosenbaum, MD, Hari Parameswaran, MD, MS, Marcelo C Pasquini, MD, MS, Mary M. Horowitz, MD, MS, Thomas C. Shea, MD, Steven M Devine, MD, Charles Linker, MD

Blood (2010) 116 (21): 37.

https://doi.org/10.1182/blood.V116.21.37.37

Published: 2010

Journal Articles

Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease

Blood (2010) 116 (21): 211.

https://doi.org/10.1182/blood.V116.21.211.211

Published: 2010

Journal Articles

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, Rosalie Odchimar-Reissig, Amanda LeBlanc, Vesna Najfeld, Janice Gabrilove, Luis Isola, Igor Espinoza-Delgado, MD, James Zwiebel

Blood (2008) 112 (11): 3656.

https://doi.org/10.1182/blood.V112.11.3656.3656

Published: 2008

Journal Articles

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

Thomas C. Shea, MD, Jeffrey Johnston, MA, William Walsh, MD, Sherif Farag, MD, PhD, John McCarty, MD, Asad Bashey, MD, PhD, Luis Isola, MD, Marc Stewart, MD, Michael Kelly, MA, Kouros Owzar, PhD, Charles Linker, MD

Blood (2007) 110 (11): 486.

https://doi.org/10.1182/blood.V110.11.486.486

Published: 2007

Journal Articles

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

Partow Kebriaei, MD, Luis Isola, MD, Erkut Bahceci, MD, H. Kent Holland, MD, Scott Rowley, MD, Joseph McGuirk, DO, Marcel Devetten, MD, Jan Jansen, MD, PhD, Roger Herzig, MD, Michael Schuster, MD, Joseph Uberti, MD, PhD

Blood (2006) 108 (11): 3231.

https://doi.org/10.1182/blood.V108.11.3231.3231

Published: 2006

Journal Articles

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Janice L. Gabrilove, MD, Melanie-Jane McConnell, MD, Windy Berkofsky-Fessler, MD, Andres L. Sirulnik, MD, PhD, Sanjay Sharma, MD, Lewis R. Silverman, MD, Luis Isola, MD, John Mandeli, PhD, Jonathan Licht, MD

Blood (2005) 106 (11): 2799.

https://doi.org/10.1182/blood.V106.11.2799.2799

Published: 2005

Journal Articles

Homeostasis of Human Langerhans Cells after Allogeneic Hematopoietic Stem Cell Transplantation.

Milena Bogunovic, MD, Laurie Chicha, PhD, Luis Isola, MD, Florent Ginhoux, PhD, Paul S. Frenette, MD, PhD, Markus G. Manz, MD, Merad Miriam, MD, PhD

Blood (2005) 106 (11): 3092.

https://doi.org/10.1182/blood.V106.11.3092.3092

Published: 2005

Journal Articles

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Richard R. Furman, MD, Genadi Iosava, MD, Luis Isola, MD, Farhad Ravandi, MD, Mamia Zodelava, MD, J. Claude Bennett, MD, J. Michael Kilpatrick, PhD, Shanta Bantia, PhD, Fodosine Development Group

Blood (2005) 106 (11): 881.

https://doi.org/10.1182/blood.V106.11.881.881

Published: 2005

Journal Articles

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Eileen Scigliano, MD, Celia Grosskreutz, MD, Steven Fruchtman, MD, Janice Gabrilove, MD, John Mandeli, PhD, Luis Isola, MD

Blood (2005) 106 (11): 5315.

https://doi.org/10.1182/blood.V106.11.5315.5315

Published: 2005

Journal Articles

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

Luis Isola, MD, Richard R. Furman, MD, Varsha Gandhi, PhD, Deborah A. Thomas, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 4501.

https://doi.org/10.1182/blood.V104.11.4501.4501

Published: 2004

Journal Articles

A Murine Model for Human Cord Blood Transplantation: Near-Term Fetal and Neonatal Peripheral Blood Cells Can Achieve Long-Term Bone Marrow Engraftment in Sublethally Irradiated Adult Recipients

Andromachi Scaradavou, Luis Isola, Pablo Rubinstein, Yelena Galperin, Vesna Najfeld, David Berlin, Jon Gordon, Rona S. Weinberg

Blood (1997) 89 (3): 1089–1099.

https://doi.org/10.1182/blood.V89.3.1089

Published: 1997

NARROW

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis

Pharmacoeconomic Impact of Upfront Use Plerixafor for Autologous Stem Cell Mobilization in Multiple Myeloma Patients

Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis

Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis

Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease

A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium

Reduced Intensity Allogeneic Transplantation Provides High Disease-Free and Overall Survival in Patients (Pts) with Advanced Indolent NHL and CLL: CALGB 109901.

Phase II Trial of Prochymal™ (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD).

A Phase I-II Pilot Study of Divalproex Sodium Alone and in Combination with All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia.

Homeostasis of Human Langerhans Cells after Allogeneic Hematopoietic Stem Cell Transplantation.

Forodesine (Fodosine TM ), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study).

Phase I Study of Rituximab-Cyclophosphamide (R-CY) Stem Cell Mobilization and Rituximab-BEAM HDC with ASCT in Patients with Relapsed, Refractory or High Risk Intermediate Grade Non-Hodgkin’s Lymphoma.

Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

A Murine Model for Human Cord Blood Transplantation: Near-Term Fetal and Neonatal Peripheral Blood Cells Can Achieve Long-Term Bone Marrow Engraftment in Sublethally Irradiated Adult Recipients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only